Prodromal Parkinson'S Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Prodromal Parkinson's Disease refers to the preclinical and early symptomatic phase of Parkinson's Disease (PD) that occurs before the classic motor symptoms are fully [1]
manifested.[2] This stage is characterized by the presence of non-motor features and subtle motor signs that [3]
precede the diagnosis of clinically established PD by years or even decades.[1:1] The prodromal phase represents a critical window for potential neuroprotective interventions and early diagnosis.[2:1], [1:2] This stage is characterized by the presence [4]
of non-motor features and subtle motor signs that precede the diagnosis of clinically established PD by years or even decades. The prodromal phase represents a critical window for
potential neuroprotective interventions and early diagnosis.[2:2], [1:3]
Prodromal Parkinson's Disease is defined as the period during which pathological processes are ongoing but the classic triad of resting tremor, bradykinesia, and rigidity have not
yet met the diagnostic threshold for clinically established PD.[2:3] According to the International Parkinson's and
Movement Disorders Society (MDS), prodromal PD is characterized by the presence of specific markers that indicate an increased risk of developing PD.[2:4], [5]
The MDS research criteria for prodromal PD incorporate various risk factors and prodromal markers, including:
Several genetic factors increase the risk of prodromal PD:[1:4]
The non-motor symptoms of prodromal PD often precede motor symptoms by years:[3:2]
Sleep Disorders
Olfactory Dysfunction
Autonomic Dysfunction
Neuropsychiatric Symptoms
Cognitive Changes
Subtle motor abnormalities may be present in prodromal PD:
The progression from prodromal to clinically established PD varies significantly among individuals:[6:2]
The average time from prodromal markers to clinical diagnosis is 10-20 years, though this can vary widely.[1:5], [8:1], [9:1]
Identifying prodromal PD is crucial because:
While no disease-modifying therapy has been proven to slow or halt prodromal PD progression, several strategies are being investigated:
Lifestyle Modifications
Potential Pharmacologic Interventions
Monitoring and Follow-up
Several conditions can present with prodromal features similar to PD:
Several ongoing studies are focused on prodromal PD:
Clinical trials targeting prodromal PD patients are evaluating.[10], [4:1]
The study of Prodromal Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent publications on prodromal Parkinson's disease.
Postuma and Berg, Prodromal Parkinson's Disease: The Decade Past, the Decade to Come (2019). 2019. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Berg et al. MDS research criteria for prodromal Parkinson's Disease (2015). 2015. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Schenck et al. Delayed emergence of a parkinsonian disorder in 38 older men initially diagnosed with idiopathic REM sleep behavior disorder (1996). 1996. ↩︎ ↩︎ ↩︎
Mirelman et al. Defining and capturing the prodromal phase of Parkinson's Disease in clinical trials (2023). 2023. ↩︎ ↩︎
de Klerk et al. A retrospective study of the MDS criteria for prodromal Parkinson's Disease in the general population (2024). 2024. ↩︎ ↩︎
Iranzo et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder (2014). 2014. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Postuma et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder (2019). 2019. ↩︎ ↩︎ ↩︎
Pilotto et al. Application of the MDS prodromal Parkinson's Disease research criteria in two prospective cohorts (2017). 2017. ↩︎ ↩︎
Ponsen et al. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's Disease (2010). 2010. ↩︎ ↩︎
McFarthing et al. Parkinson's Disease drug therapies in the clinical trial pipeline: 2023 update (2023). 2023. ↩︎ ↩︎